{"id":"NCT03297216","sponsor":"University of North Carolina, Chapel Hill","briefTitle":"Improving Pregnancy Outcomes With Progesterone","officialTitle":"Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-07","primaryCompletion":"2020-06-25","completion":"2020-08-06","firstPosted":"2017-09-29","resultsPosted":"2021-07-09","lastUpdate":"2021-07-22"},"enrollment":800,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pre-term Birth","HIV-1-infection"],"interventions":[{"type":"DRUG","name":"17P","otherNames":["17-alpha hydroxyprogesterone caproate"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"250 mg 17P","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase III, double-masked, placebo-controlled, randomized controlled trial taking place in Zambia.","primaryOutcome":{"measure":"Number of Participants Experiencing Preterm Births or Stillbirths","timeFrame":"At delivery, up to 37 weeks of gestation for live births and up to approximately 40 weeks of gestation for stillbirths","effectByArm":[{"arm":"250 mg 17P","deltaMin":36,"sd":null},{"arm":"Placebo","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":2,"countries":["Zambia"]},"refs":{"pmids":["34509197","30813934"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":399},"commonTop":["Headache","Diarrhea"]}}